The subsidiary of Shutaishen (300204.SZ) is included in the national medical insurance catalogue for injectable bomitase α

Zhitongcaijing · 2d ago

According to the Zhitong Finance App, Shu Taishen (300204.SZ) announced that the products of the company's subsidiary Jiangsu Beijietai Biotechnology Co., Ltd.'s injectable bomitase α (bojianin) were included in the “2026 National Medical Insurance Catalogue”. The drug is indicated for bleeding treatment in adult patients with congenital hemophilia A or B with coagulation factor VIII or IX inhibitors > 5 Bethesda units (BU). The inclusion of this drug in the national medical insurance catalogue will help reduce the burden of medication use on patients, improve the accessibility of the drug, and expand the number of beneficiary groups.